Clinical Trial Update: Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity [Phase 2]

View source ↗

Summary

Pfizer's Phase 2 trial of CP-741,952 for obesity was terminated. The update discusses safety, toleration and potential efficacy signals observed during the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• CP-741,952

Snippet

Sponsor: Pfizer | Conditions: Obesity | Phase 2 | Status: TERMINATED